Cargando…

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma

Background: As a major subtype of ovarian cancer, high grade FIGO stage IIIc serous ovarian carcinoma (HG3cSOC), has various prognosis due to genetic heterogeneity. Methods: The transcriptome of 401 primary FIGO IIIc serous ovarian samples was screened, seven genes based prognostic model was develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Gang, Chen, Lihua, Ren, He, Liu, Fei, Dong, Chuanpeng, Wu, Aosen, Liu, Zhenhao, Zheng, Yu, Cheng, Xi, Liu, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299362/ https://www.ncbi.nlm.nih.gov/pubmed/30585265 http://dx.doi.org/10.7150/ijbs.28249

Ejemplares similares

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

Panel of seven long noncoding RNA as a candidate prognostic biomarker for ovarian cancer
por: Zhan, Xiaohui, et al.
Publicado: (2017)

Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
por: Poschner, Stefan, et al.
Publicado: (2020)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
por: Boyraz, Gökhan, et al.
Publicado: (2017)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
por: Tomar, Tushar, et al.
Publicado: (2017)

Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma
por: Lin, Hao, et al.
Publicado: (2021)

PTPN13 Participates in the Regulation of Epithelial–Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells
por: Aptecar, Leticia, et al.
Publicado: (2023)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer
por: Wang, Wei, et al.
Publicado: (2019)

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
por: Silva Raju, Janisha, et al.
Publicado: (2021)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer
por: Zhu, Yan, et al.
Publicado: (2022)

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
por: Kahramanoğlu, İlker, et al.
Publicado: (2018)

Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity
por: Liu, Suxia, et al.
Publicado: (2023)

Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
por: Liu, Rong, et al.
Publicado: (2017)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines
por: Piscazzi, Annamaria, et al.
Publicado: (2022)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
por: Hillman, R Tyler, et al.
Publicado: (2017)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
por: Reid, Brett M., et al.
Publicado: (2021)

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study
por: Ren, Yulan, et al.
Publicado: (2015)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2017)

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
por: Kieffer, Yann, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q4o10qi2ojhgbktsa12hggu6i5